Back to Search Start Over

A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.

Authors :
Charpentier B
Rostaing L
Berthoux F
Lang P
Civati G
Touraine JL
Squifflet JP
Vialtel P
Abramowicz D
Mourad G
Wolf P
Cassuto E
Moulin B
Rifle G
Pruna A
Merville P
Mignon F
Legendre C
Le Pogamp P
Lebranchu Y
Toupance O
Hurault De Ligny B
Touchard G
Olmer M
Purgus R
Pouteil-Noble C
Glotz D
Bourbigot B
Leski M
Wauters JP
Kessler M
Source :
Transplantation [Transplantation] 2003 Mar 27; Vol. 75 (6), pp. 844-51.
Publication Year :
2003

Abstract

Background: Induction therapy with antithymocyte globulin (ATG) reduces the incidence of acute rejection after transplantation. A study was undertaken to assess the efficacy and safety of ATG induction on tacrolimus-based and cyclosporine A (CsA)-based therapies compared with immediate tacrolimus triple therapy in kidney transplant recipients.<br />Methods: In a 6-month, open-label, randomized, prospective study conducted in 30 European centers, 555 renal transplant patients were randomly assigned to tacrolimus triple therapy (Tac triple, n=185), ATG induction with tacrolimus (ATG-Tac, n=186), or ATG induction with CsA microemulsion (ATG-CsA, n=184); all were combined with azathioprine and corticosteroids. The primary endpoint was incidence and time to first acute rejection episode confirmed by biopsy.<br />Results: Patient demographics and clinical parameters at baseline were similar. Patient and graft survival rates were similar in all groups. The incidence of clinically apparent acute rejection was significantly higher (P=0.003) for Tac triple (33.0%) compared with ATG-Tac (22.6%) and the incidence for ATG-Tac was significantly lower (P=0.004) than for ATG-CsA (37.0%). The incidences of acute rejection confirmed by biopsy (primary endpoint) were 25.4%, 15.1%, and 21.2% for Tac triple, ATG-Tac, and ATG-CsA, respectively (Tac triple vs. ATG-Tac, P=0.004). The incidences of corticosteroid-resistant acute rejection were 7.0% (Tac triple), 4.8% (ATG-Tac), and 10.9% (ATG-CsA) (ATG-Tac vs. ATG-CsA, P=0.038). In the ATG groups, the incidences of leukopenia, thrombocytopenia, serum sickness, fever, and cytomegalovirus infection were significantly higher (P<0.05).<br />Conclusions: Acute rejection was significantly lower in the ATG-Tac group compared with the ATG-CsA and Tac triple groups. Significantly more hematologic and infectious adverse events were observed in both ATG induction groups.

Details

Language :
English
ISSN :
0041-1337
Volume :
75
Issue :
6
Database :
MEDLINE
Journal :
Transplantation
Publication Type :
Academic Journal
Accession number :
12660513
Full Text :
https://doi.org/10.1097/01.TP.0000056635.59888.EF